专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013010170A1 PROCESS FOR DETECTION OF ALZHEIMER'S DISEASE FROM A SERUM SAMPLE 审中-公开
标题翻译：从血清样品中检测阿尔茨海默病的方法
公开(公告)号：WO2013010170A1
公开(公告)日：2013-01-17
申请号：PCT/US2012/046925
申请日：2012-07-16
申请人： LOVELL, Mark, A. , LYNN, Bert, C.
发明人： LOVELL, Mark, A. , LYNN, Bert, C.
IPC分类号： G01N33/68
CPC分类号： G01N33/54306 , G01N33/6896 , G01N2333/76 , G01N2333/99 , G01N2800/2821
摘要： Disclosed is a method of detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI). Also disclosed is a process for detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI) comprising (a) detecting a first concentration of lipocalin-PDS/TTR complex in a blood sample or urine sample from the subject, (b) determining a second concentration of PDS/TTR complex in a blood sample or urine sample from an unaffected individual, and (c) comparing the first and second concentrations, wherein a lower first concentration as compared to the second concentration is indicative of the subject having or being at risk of developing Alzheimer's disease.
摘要翻译：公开了一种检测具有或有发生阿尔茨海默病或轻度认知障碍（MCI）风险的人类受试者的生物标志物的浓度的方法。还公开了一种用于检测患有或有发展为阿尔茨海默氏病或轻度认知障碍（MCI）的风险的人类受试者的生物标志物的浓度的方法，其包括（a）检测血液中脂质运载蛋白-PDD / TTR复合物的第一浓度（b）确定来自未受影响个体的血液样品或尿液样品中的PDS / TTR复合物的第二浓度，和（c）比较第一和第二浓度，其中比较第一和第二浓度到第二浓度表明受试者具有或有发展为阿尔茨海默氏病的风险。

2. 发明申请

WO2008014314A3 BIOMARKERS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE 审中-公开
标题翻译：轻度认知障碍和阿尔茨海默病的生物标志物
公开(公告)号：WO2008014314A3
公开(公告)日：2008-10-23
申请号：PCT/US2007074309
申请日：2007-07-25
申请人： UNIV KENTUCKY RES FOUND , LOVELL MARK A , LYNN BERT C
发明人： LOVELL MARK A , LYNN BERT C
IPC分类号： G01N33/53 , G01N33/537 , G01N33/543 , G01N33/566
CPC分类号： G01N33/6896 , G01N2800/2821
摘要： A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu-Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein.
摘要翻译：一种用于量化患者中的神经退行性病症的方法，其包括从受试者获得流体样品; 测量所述流体样品中的蛋白质生物标志物复合物，并将测量结果与轻度认知障碍或阿尔茨海默病状态相关联。生物标志物包括那些包含转甲状腺素蛋白和/或前列腺素-H2D-异构酶蛋白中的至少一种和至少一种选自转甲状腺素蛋白，前列腺素-H2D异构酶，β2-微球蛋白，半胱氨酸蛋白酶抑制剂C，超氧化物歧化酶[Cu-Zn]，血浆视黄醇结合蛋白，磷脂酰乙醇胺结合蛋白，碳酸酐酶2，前列腺素-H 2 D-异构酶和/或血清转铁蛋白蛋白。

3. 发明申请

WO2008014314A2 BIOMARKERS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE 审中-公开
标题翻译：生物标志物的消化不良和阿尔茨海默病
公开(公告)号：WO2008014314A2
公开(公告)日：2008-01-31
申请号：PCT/US2007/074309
申请日：2007-07-25
申请人： UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION , LOVELL, Mark A. , LYNN, Bert C.
发明人： LOVELL, Mark A. , LYNN, Bert C.
IPC分类号： G01N33/567 , G01N33/53
CPC分类号： G01N33/6896 , G01N2800/2821
摘要： A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu-Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein.
摘要翻译：一种用于量化患者中的神经变性疾病的方法，包括从受试者获得流体样品; 测量所述流体样品中的蛋白质生物标志物复合物，并将测量与轻度认知障碍或阿尔茨海默病状态相关联。生物标志物包括那些包含转甲状腺素蛋白和/或前列腺素-H2 D-异构酶蛋白中的至少一种和至少一种选自转甲状腺素蛋白，前列腺素-H2 D-异构酶，β-2-微球蛋白，半胱氨酸蛋白酶抑制剂C，超氧化物歧化酶[Cu-Zn]，血浆视黄醇结合蛋白，磷脂酰乙醇胺结合蛋白，碳酸酐酶2，前列腺素-H2 D-异构酶和/或血清转铁蛋白。

4. 发明申请

WO2011142778A1 TREATMENT OF MCI AND ALZHEIMER'S DISEASE 审中-公开
标题翻译：治疗MCI和阿尔茨海默病
公开(公告)号：WO2011142778A1
公开(公告)日：2011-11-17
申请号：PCT/US2010/057287
申请日：2010-11-18
申请人： THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION , LOVELL, Mark , LYNN, Bert
发明人： LOVELL, Mark , LYNN, Bert
IPC分类号： A01N43/40
CPC分类号： A61K31/44 , A61K31/4422 , A61K2300/00
摘要： The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic- i ), e.g., NFD- L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.
摘要翻译：本发明尤其提供了可以有效治疗，减缓或预防神经系统疾病（例如，神经变性疾病，例如轻度认知障碍（MCI）或阿尔茨海默病（AD）））的治疗组合物和方法，特别是，基于治疗有效量的硝苯地平，氧化或亚硝基硝苯吡啶衍生物，内酰胺（例如，式（Ic）或（Ic-i）的化合物，例如NFD-L1），甲状腺素（T4），三碘甲状腺原氨酸（T3）它们。

5. 发明申请

WO2010132671A1 TREATMENT OF MCI AND ALZHEIMER'S DISEASE 审中-公开
标题翻译：治疗MCI和阿尔茨海默病
公开(公告)号：WO2010132671A1
公开(公告)日：2010-11-18
申请号：PCT/US2010/034721
申请日：2010-05-13
申请人： THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION , LOVELL, Mark , LYNN, Bert
发明人： LOVELL, Mark , LYNN, Bert
IPC分类号： C07D211/02
CPC分类号： A61K31/44 , A61K31/198 , A61K2300/00
摘要： The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent mild cognitive impairment (MCI) or Alzheimer's disease (AD), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, thyroxine (T4), triiodothyronine (T3) and combinations thereof.
摘要翻译：本发明尤其提供了可以有效治疗，缓慢或预防轻度认知障碍（MCI）或阿尔茨海默病（AD）的治疗组合物和方法，特别是基于治疗有效量的硝苯地平，氧化或亚硝基硝苯地平衍生物，甲状腺素（T4），三碘甲状腺原氨酸（T3）及其组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式